Apeloa Pharmaceutical Co.,Ltd (SHE:000739)
China · Delayed Price · Currency is CNY 19.37
-0.13 (-0.67%)
Oct 30, 2026, 3:04 PM CST
SHE:000739 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 21,767 | 18,685 | 18,836 | 17,996 | 25,222 | 41,354 | |
Market Cap Growth | 20.96% | -0.80% | 4.67% | -28.65% | -39.01% | 50.73% |
Enterprise Value | 19,848 | 16,385 | 15,909 | 15,202 | 22,812 | 39,127 |
Last Close Price | 19.37 | 15.98 | 15.24 | 14.14 | 19.48 | 31.37 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 27.80 | 20.98 | 18.27 | 17.05 | 25.50 | 43.28 |
Forward PE | 13.84 | 12.61 | 14.93 | 12.47 | 22.39 | 32.10 |
PS Ratio | 2.46 | 1.91 | 1.57 | 1.57 | 2.39 | 4.62 |
PB Ratio | 3.39 | 2.94 | 2.79 | 2.89 | 4.57 | 8.17 |
P/TBV Ratio | 3.57 | 3.11 | 2.94 | 3.06 | 4.89 | 8.81 |
P/FCF Ratio | 32.06 | 22.40 | 25.18 | 44.89 | 30.87 | - |
P/OCF Ratio | 19.42 | 15.31 | 15.58 | 17.45 | 19.02 | 67.60 |
PEG Ratio | - | 1.08 | 1.08 | 1.08 | 1.08 | 1.15 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 2.24 | 1.68 | 1.32 | 1.33 | 2.16 | 4.38 |
EV/EBITDA Ratio | 12.33 | 10.64 | 10.10 | 9.32 | 17.60 | 29.69 |
EV/EBIT Ratio | 22.89 | 18.67 | 15.72 | 14.11 | 25.16 | 40.78 |
EV/FCF Ratio | 29.24 | 19.65 | 21.27 | 37.92 | 27.92 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.23 | 0.24 | 0.14 | 0.15 | 0.15 | 0.09 |
Debt / EBITDA Ratio | 0.91 | 0.98 | 0.57 | 0.56 | 0.65 | 0.36 |
Debt / FCF Ratio | 2.17 | 1.82 | 1.22 | 2.30 | 1.02 | - |
Net Debt / Equity Ratio | -0.30 | -0.36 | -0.41 | -0.43 | -0.49 | -0.42 |
Net Debt / EBITDA Ratio | -1.20 | -1.47 | -1.75 | -1.63 | -2.10 | -1.63 |
Net Debt / FCF Ratio | -2.84 | -2.72 | -3.68 | -6.64 | -3.32 | 23.85 |
Asset Turnover | 0.73 | 0.78 | 0.94 | 0.93 | 1.00 | 1.08 |
Inventory Turnover | 3.93 | 4.22 | 4.68 | 4.44 | 5.29 | 5.63 |
Quick Ratio | 1.15 | 1.15 | 1.05 | 0.94 | 0.95 | 1.13 |
Current Ratio | 1.52 | 1.47 | 1.43 | 1.33 | 1.29 | 1.53 |
Return on Equity (ROE) | 12.44% | 13.60% | 15.88% | 17.96% | 18.70% | 20.22% |
Return on Assets (ROA) | 4.45% | 4.38% | 4.96% | 5.44% | 5.38% | 7.25% |
Return on Invested Capital (ROIC) | 15.14% | 18.16% | 22.91% | 29.63% | 31.03% | 30.94% |
Return on Capital Employed (ROCE) | 12.30% | 12.60% | 14.50% | 16.70% | 15.10% | 18.20% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 3.60% | 4.77% | 5.47% | 5.86% | 3.92% | 2.31% |
FCF Yield | 3.12% | 4.46% | 3.97% | 2.23% | 3.24% | -0.22% |
Dividend Yield | 1.44% | 3.54% | 2.19% | 2.06% | 1.38% | 0.81% |
Payout Ratio | 45.34% | 93.87% | 38.95% | 36.29% | 36.68% | 31.60% |
Buyback Yield / Dilution | 0.17% | 0.86% | 0.52% | 0.40% | 0.38% | 0.00% |
Total Shareholder Return | 1.60% | 4.40% | 2.71% | 2.46% | 1.75% | 0.81% |